MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding MoonLake Immunotherapeutics changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 23 | 24 | +1 |
| Shares | 36.5M | 36.9M | +385.8K (+1.1%) |
| Value | $190.1M | $291.4M | +$101.3M (+53.3%) |
New holders (5)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 335,000 | $2.60M | 0.01% |
| Tekla Capital Management LLC | 300,000 | $2.39M | 0.10% |
| Balyasny Asset Management LLC | 99,874 | $795.0K | 0.00% |
| Jefferies Group LLC | 67,654 | $525.0K | 0.02% |
| Morgan Stanley | 3,100 | $24.0K | 0.00% |
Sold out (4)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Millennium Management LLC | 28,090 | $147.0K |
| Cowen and Company, LLC | 16,173 | $85.0K |
| Penserra Capital Management LLC | 3,195 | $16.0K |
| Tower Research Capital LLC (TRC) | 25 | $0 |